• Compounds from the azole group (eg ketoconazole) increase the concentration of cyclorporine in the blood. Ketoconazole at 5-10 mg/kg increases the concentration of cyclosporine in the blood up to 5 times. Macrolides such as erythromycin can double the plasma levels of cyclosporine. Certain inducers such as cytochrome P450, epilepsy treatments, and antibiotics (eg, trimethoprim/sulfonamide) may reduce the plasma concentration of ciclosporin. Simultaneous administration with P-glycoprotein substrates (such as macrocyclic lactones: ivermectin and milbemycin) could reduce the outflow of these active substances, giving signs of CNS toxicity.
• Cyclosporine can increase the nephrotoxicity of aminoglycoside antibiotics and trimethoprim, so its concomitant use is not recommended.

CYCLAVANCE

Dogs: Treatment of clinical manifestations of atopic dermatitis.

• Hypersensitivity to the active substance or to any of its components.
• Dogs less than 6 months of age or less than 2 kg in weight.
• Historical malignant disorders or progressive malignant disorders, nor in animals with diabetes.
• Do not vaccinate with live vaccines during treatment or during 2 weeks intervals after or before treatment.

• Gastrointestinal disorders such as vomiting, feces, mucosa, soft and diarrhea. These reactions are mild and transient and do not require discontinuation of treatment.
• Less frequently: Lethargy or hyperactivity, anorexia, mild to moderate gingival hyperplasia, skin reactions, verruciform lesions, coat changes, redness or swelling of the pinna, muscle weakness or cramps.
• Transient moderate salivation.
• In very rare cases diabetes mellitus especially in West Highland White Terriers.

Dogs: 5 mg/kg of bw (0,05 ml of oral solution per kg of bw) 2 hours before or after meals, introducing the dosing syringe into the animal's mouth.
Initially administer daily until satisfactory clinical improvement is obtained (4-8 weeks). If there is no improvement in 8 weeks, stop the treatment. If the symptoms are satisfactorily controlled, administer every 2 days and carry out clinical controls to adjust the frequency.

• In laboratory animals at high doses it is embryotoxic and fetotoxic: In reproductives and pregnant women assess benefit risk.
• With kidney disease monitor creatinine.

Do not refrigerate. Once opened, do not store above 25 °C.

5, 15, 30 or 50 ml with dispenser cap and graduated syringe.

CYCLAVANCE